

BioPharma

Latest Updates

Here are this week's BioPharma updates - **October 20th, 2025.**

Funding

- [Kailera Therapeutics](#) (MA, USA) raised \$600M in Series B funding to advance its late-stage obesity pipeline, including global Phase 3 trials of KAI-9531, an injectable GLP-1/GIP dual agonist.
- [Tubulis](#) (Munich, Germany) raised \$361M in Series C funding to expand clinical development of TUB-040, its lead antibody-drug conjugate for ovarian and lung cancers, and to advance additional ADC programs and platform technologies.
- [Lila Sciences](#) (MA, USA) raised \$350M in Series A funding, bringing total capital to \$550M, to expand its AI-driven "Science Factories" and commercialize its scientific superintelligence platform for life sciences, chemistry, and materials discovery.
- [Kardigan](#) (CA, USA) raised \$254M in Series B funding to advance its late-stage portfolio of personalized cardiovascular medicines for dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis.
- [Expedition Therapeutics](#) (CA, USA) raised \$165M in Series A funding to advance EXPD-101, a Phase 2-ready, once-daily oral DPP1 inhibitor for chronic obstructive pulmonary disease and other neutrophil-driven diseases.
- [Arthrosi Therapeutics](#) (CA, USA) raised \$153M in Series E funding to complete pivotal Phase 3 development of pozdeutinurad (AR882) for the treatment of gout and tophaceous gout.
- [Pelage Pharmaceuticals](#) (CA, USA) raised \$120M in Series B funding to advance PP405, a topical regenerative therapy that reactivates dormant hair follicle stem cells, into Phase 3 trials for androgenetic alopecia in 2026.
- [Nilo Therapeutics](#) (NY, USA) launched with \$101M in Series A funding to develop a new class of medicines that harness neural circuits to restore immune balance in autoimmune and inflammatory diseases.

- [TORL BioTherapeutics](#) (CA, USA) raised \$96M in Series C funding to advance clinical development of TORL-1-23, a Claudin 6-targeted antibody-drug conjugate for platinum-resistant ovarian and other CLDN6+ cancers.
- [RealSense](#) (CA, USA) spun out from Intel and raised \$50M in Series A funding to scale its AI-powered vision technology and collaborate with NVIDIA to advance perception systems for humanoid and autonomous mobile robots.
- [Kernal Bio](#) (MA, USA) received up to \$48M from ARPA-H to advance its in vivo mRNA-encoded CAR T-cell therapy program KR-402 for hematological cancers and autoimmune diseases.
- [Tessera Therapeutics](#) (MA, USA) received up to \$41.3M from ARPA-H to develop single-dose in vivo CAR-T therapies using its Gene Writing™ and lipid nanoparticle delivery platforms for cancer and autoimmune diseases.
- [Step Pharma](#) (Saint-Genis-Pouilly, France) raised \$41M in Series C funding to advance clinical development of *dencatostat*, a first-in-class CTPS1 inhibitor being tested for lymphoma, solid tumors, and essential thrombocythaemia.
- [BioNTech](#) (Kigali, Rwanda) received a \$40M grant to expand its mRNA vaccine manufacturing facility producing vaccines for diseases including malaria, tuberculosis, HIV, and mpox.
- [Jupiter Endovascular](#) (CA, USA) raised over \$40M in Series B funding to complete its SPIRARE II pivotal trial, prepare for commercialization, and expand clinical applications of its Transforming Fixation (TFX) platform.
- [Affinia Therapeutics](#) (MA, USA) raised \$40M in Series C funding to advance AFTX-201, a gene therapy for BAG3 dilated cardiomyopathy, and support its broader cardiovascular and neurological gene therapy pipeline.
- [ABK Biomedical](#) (Halifax, Canada) raised \$35M in Series D funding to support clinical operations, commercialization of Eye90 microspheres®, and continued product development in interventional oncology.
- [Omnix Medical](#) (Jerusalem, Israel) raised \$25M in Series C funding to complete Phase II proof-of-concept studies of *OMN6*, a first-in-class antimicrobial peptide for treating multidrug-resistant Gram-negative infections, and to advance its broader anti-infective pipeline.
- [AeroRx Therapeutics](#) (CA, USA) raised \$21M in Series A funding to advance AERO-007, a once-daily nebulized LABA/LAMA therapy for chronic obstructive pulmonary disease, into late-stage clinical development.
- [Mission Therapeutics](#) (Cambridge, United Kingdom) raised \$13.3M in funding to fund a Phase 1b proof-of-mechanism clinical trial of MTX325, a first-in-class, potentially disease-modifying treatment for Parkinson's disease.

- [Ascribe Bio](#) (NY, USA) raised \$12M in Series A funding to launch Phytalix®, a next-generation biofungicide providing sustainable and affordable disease control for global agriculture.
- [4D Molecular Therapeutics](#) (CA, USA) received up to \$11M in additional funding from the Cystic Fibrosis Foundation to advance 4D-710, a genetic therapy for cystic fibrosis lung disease, into Phase 2 clinical development.
- [EVerZom](#) (Strasbourg, France) raised \$10.8M in funding to initiate clinical development of EVerGel™, an exosome-based therapy for Crohn's perianal fistula, and to scale its GMP exosome biomanufacturing platform.
- [VitriVax](#) (CO, USA) received a \$9.9M Gates Foundation grant to scale up GMP manufacturing for its ALTA® vaccine formulation technology and prepare for Phase 1 clinical trials.
- [Amplifi Vascular](#) (MO, USA) raised \$6.9M in Series A funding to advance its Vein Dilation System, designed to improve arteriovenous fistula creation and maturation for hemodialysis patients.
- [Kneu Health](#) (London, United Kingdom) raised \$5.6M in seed funding to scale its FDA-cleared smartphone platform for continuous monitoring and early detection of neurological decline in Parkinson's and dementia patients.
- [VeraMorph](#) (MA, USA) received a \$5M SBIR Fast Track grant from the National Cancer Institute to advance development of the first effective oral fulvestrant therapy for estrogen receptor-positive metastatic breast cancer.
- [Neuronoff](#) (OH, USA) raised \$4.5M in funding to advance its minimally invasive Injectrode® platform toward FDA clearance and commercial launch for the treatment of chronic pain.
- [Daré Bioscience](#) (CA, USA) received a \$4M grant installment, bringing total funding to \$41.8M of a \$49M commitment, to advance its smart drug delivery device DARE-LARC1 for long-acting contraception.
- [EVOQ Therapeutics](#) (MI, USA) received a \$2M NIH grant to advance development of its NanoDisc-based therapy for celiac disease, aiming to reeducate the immune system and restore immune tolerance.
- [DemeRx](#) (FL, USA) received a \$1.7M NIH SBIR grant to advance DMX-1001, a neuroplastogen drug candidate for treating alcohol use disorder through a novel mechanism that promotes neuroplasticity and reduces relapse risk.
- [Confo Therapeutics](#) (Ghent, Belgium) received a \$1.1M VLAIO grant to develop ultra-long-acting antibody-based GPCR therapeutics for metabolic and endocrine disorders, including obesity.
- [HistoSonics](#) (MI, USA) raised \$250M in oversubscribed growth financing to support the commercial expansion of its Edison® histotripsy platform and advanced clinical programs.

- [Veradermics](#) (UT, USA) raised \$150M in oversubscribed Series C financing to advance VDPHL01 through multiple Phase 3 trials as a potential first non-hormonal oral therapeutic for hair regrowth in women and men.
- [Adcytherix](#) (Paris, France) raised \$114M in Series A financing to accelerate its antibody-drug conjugate pipeline with a strategic focus on novel payloads.
- [Peptilogics](#) (PA, USA) raised \$78M to advance its lead peptide therapeutic, zaloganan, into a pivotal trial targeting serious infections.
- [BridGene Biosciences](#) (CA, USA) raised \$28M in Series B financing to accelerate clinical development of its oncology candidate BGC-515 and expand its IMTAC™ platform.
- [Monod Bio](#) (WA, USA) received a \$750K Grand Challenges grant to develop a rapid, AI-designed protein-based diagnostic for preeclampsia to improve maternal health in low-resource settings.
- [TruDiagnostic](#) (KY, USA) received an NIH Small Business Innovation Research (SBIR) grant to advance its W-Function Epigenomic Roadmap, a next-generation diagnostic model that tracks dynamic DNA methylation changes to improve prediction and prevention of chronic diseases such as cardiovascular disease and type 2 diabetes.
- [Aphios Corporation](#) (MA, USA) received an NIH SBIR Phase I grant to advance development of Zindol®, a ginger-derived botanical drug for treating chemotherapy-induced nausea and vomiting.
- [Aarvik Therapeutics](#) (CA, USA) raised an undisclosed amount in a Series Seed 2 round, including investment from Laurus Labs, to advance its pipeline of next-generation antibody-drug conjugates developed using its MUTTA™ platform.
- [Cytiva](#) (MA, USA) received ARPA-H funding to develop an in vivo CAR-T therapy platform for gastrointestinal cancers, aiming to target solid tumors and reduce manufacturing costs by tenfold.

Emerging

- [Excellergy](#) (CA, USA) launched with \$70M in Series A financing to advance its portfolio of first-in-class *Effector Cell Response Inhibitors (ECRIs)* — a new class of trifunctional biologics designed to rapidly remove receptor-bound IgE, neutralize free IgE, and downregulate FcεRI expression for complete allergic control.
- [ImmunoVec](#) (CA, USA) emerged from stealth with up to \$40.7M in ARPA-H EMBODY funding to advance its in vivo cell engineering platform and develop a first-in-class DNA-loaded nanoparticle therapy for autoimmune diseases.

- [Liberate Bio](#) (MA, USA) emerged from stealth with \$31M in seed funding to advance its RNA barcoding platform and develop in vivo *CAR-M* therapies targeting macrophages and monocytes, with first clinical trials planned for 2026.
- [Eldian Biomed](#) (Bern, Switzerland) received \$43,000 to advance CloudLi, an injectable microcushion therapy for osteoarthritis that targets inflammation and cartilage wear.
- [NanoZymeX](#) (Basel, Switzerland) received \$43,000 to develop a lipid nanoparticle platform for targeted enzyme delivery to treat lysosomal storage diseases, starting with Pompe disease.
- Rare Therapeutics (PA, USA) launched to develop and deliver gene therapies for ultra-orphan diseases, starting with programs targeting GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy.

Post IPO Equity

- [Praxis Precision Medicines, Inc.](#) (MA, USA) announced a \$525M underwritten public offering of common stock and pre-funded warrants to support continued development of its CNS disorder therapies targeting neuronal excitation-inhibition imbalance.
- [Apogee Therapeutics](#) (MA, USA) announced a \$300M underwritten public offering of common stock and pre-funded warrants to support advancement of its inflammatory and immunology biologics pipeline.
- [Spyre Therapeutics](#) (MA, USA) announced a \$275M underwritten public offering of common stock to support advancement of its antibody-based therapies for inflammatory bowel disease and other immune-mediated conditions.
- [EyePoint Pharmaceuticals](#) (MA, USA) announced a \$150M underwritten public offering of common stock and pre-funded warrants to advance clinical development of DURAVYU™ for wet AMD and DME, support earlier-stage pipeline programs, and for general corporate purposes.
- [Lexeo Therapeutics](#) (NY, USA) announced a \$135M underwritten public offering and concurrent private placement of common stock and pre-funded warrants to advance its genetic medicine programs for cardiovascular diseases.
- [atai Life Sciences](#) (Berlin, Germany) announced a \$130M underwritten public offering of common shares to advance clinical development of its psychedelic-based therapies for treatment-resistant depression and other mental health disorders.

- [C4 Therapeutics](#) (MA, USA) announced a \$125M underwritten public offering of common stock, pre-funded warrants, and accompanying warrants to advance clinical development of cemsidomide for multiple myeloma.
- [Propanc Biopharma, Inc.](#) (Australia) announced a strategic financing agreement of ~\$100M with Hexstone Capital LLC to accelerate clinical pipeline development and establish a \$100M Digital Asset Treasury within 12 months.
- [Idorsia Pharmaceuticals Ltd](#) (Switzerland) announced an \$81.4M accelerated bookbuilt offering of 16.4M new and treasury shares to strengthen its balance sheet and support commercialization of QUVIVIQ and pipeline advancement.
- [Rani Therapeutics](#) (CA, USA) announced a \$60.3M private placement to support the advancement of its RaniPill® oral biologics platform and extending cash runway into 2028.
- [ADC Therapeutics](#) (Lausanne, Switzerland) announced a \$60M PIPE financing to support the commercial expansion of ZYNLONTA and strengthen the balance sheet.
- [Adagio Medical Inc.](#) (CA, USA) announced a \$19M private placement of common stock and warrants to support clinical and product development and for general corporate purposes.
- [Quoin Pharmaceuticals](#) (VA, USA) announced a \$16.5M private placement to support clinical development of QRX003 for Netherton Syndrome and general corporate purposes.
- [Cardiol Therapeutics](#) (Oakville, Canada) announced an \$11M private placement of units to fund its Phase III MAVERIC trial of CardiolRx™ for recurrent pericarditis, advance its next-generation heart failure therapy CRD-38, and support operations into 2027.
- [Sharp Therapeutics](#) (PA, USA) announced a \$10M non-brokered private placement of common shares to support Phase I trials of its oral Gaucher disease candidate '901 and for working capital purposes.
- [VolitionRx](#) (NV, USA) announced a \$6M underwritten public offering of common stock and warrants, with proceeds to support research, product development, clinical studies, commercialization, and potential strategic acquisitions.
- [Conexeu Sciences Inc.](#) (Vancouver, Canada) announced a \$5M Regulation Crowdfunding (Reg CF) financing to accelerate development and commercialization of its patented collagen platform for wound care, medical aesthetics, and tissue engineering applications.

- [ENDRA Life Sciences](#) (MI, USA) announced a \$4.9M private placement to fund its new digital asset treasury strategy and support completion of its TAEUS pilot validation imaging study for MASLD/MASH.
- [Bluejay Diagnostics, Inc.](#) (MA, USA) announced a \$4.5M private placement of common stock and warrants to support FDA approval efforts, clinical studies, R&D activities, and general working capital.
- [Xenetic Biosciences](#) (MA, USA) announced a \$4.5M underwritten public offering of common stock to support working capital and general corporate purposes.
- [Theriva Biologics](#) (MD, USA) announced a \$4M warrant inducement agreement with existing institutional investors for the immediate exercise of warrants at \$0.54 per share, with proceeds supporting working capital and general corporate purposes.
- [AB Science](#) (Paris, France) announced a \$3M private placement of shares and attached warrants to support ongoing operations and advance clinical development of AB8939 in acute myeloid leukemia, including completion of Phase 1 combination therapy and initiation of an expansion study.
- [Solvonis Therapeutics](#) (London, United Kingdom) announced a ~\$1.6M direct subscription of ordinary shares to expand its CNS R&D programs across addiction, psychiatry, and neurology.
- [Maia Biotechnology, Inc.](#) (IL, USA) announced a \$736.6K private placement of common stock and warrants to support execution of Step 1 of Part C of its Phase II THIO-101 trial and for working capital.

Post IPO Debt

- [Candel Therapeutics](#) (MA, USA) announced a \$130M term loan facility to fund its Phase 3 trial of CAN-2409 in NSCLC and advance preparations for a potential prostate cancer launch.
- [Karyopharm Therapeutics](#) (MA, USA) announced a \$100M financing package comprising new term loans, convertible note exchanges, and an \$8.75M private placement of common stock and warrants to strengthen its balance sheet, extend cash runway into 2Q26, and support its Phase 3 SENTRY trial in myelofibrosis.

Mergers and Acquisitions

- [Novo Nordisk](#) (Bagsværd, Denmark) to acquire [Akeru Therapeutics](#) (CA, USA) for \$6.3B to expand its MASH portfolio. This deal will add Akeru's promising phase 3 FGF21 analogue to Novo Nordisk's pipeline, strengthening its position in metabolic and liver disease treatment.

- [Boston Scientific](#) (MA, USA) to acquire [Nalu Medical](#) (CA, USA) for \$1.7B. This deal will expand Boston Scientific's neuromodulation portfolio and strengthen its position in treating chronic pain through advanced implantable neurostimulation technologies.
- [Pure Health](#) (Abu Dhabi, United Arab Emirates) to acquire [Hellenic Healthcare Group](#) (Athens, Greece) for \$870M to strengthen its global healthcare platform. This acquisition expands PureHealth's international footprint and enhances its presence in the European healthcare market.
- [BioCryst Pharmaceuticals](#) (NC, USA) to acquire [Austria Therapeutics](#) (MA, USA) for \$648M to strengthen its presence in hereditary angioedema (HAE). This deal aims to expand BioCryst's HAE portfolio and transform its long-term growth profile.
- [TransCode Therapeutics](#) (MA, USA) to acquire [Polynoma](#) (CA, USA) for \$25M to form a first-in-class immuno-oncology and metastatic prevention company. This deal, backed by a subsidiary of CK Life Sciences, aims to advance innovative cancer therapies and expand TransCode's oncology portfolio.
- [Peli BioThermal](#) (MN, USA) to acquire [Cold Chain Technologies](#) (MA, USA) to expand cold chain logistics solutions and advance cryogenic cell and gene therapy transport. This acquisition strengthens Peli BioThermal's position in temperature-controlled packaging for the life sciences sector.
- [CytoMed Therapeutics](#) (Singapore) to acquire relevant assets of [TC BioPharm](#) (Edinburgh, United Kingdom) to expand its cell therapy capabilities. This deal aims to strengthen CytoMed's pipeline and enhance its presence in the global cell and gene therapy market.
- [Viatrix](#) (PA, USA) to acquire [Aculys Pharma](#) (Tokyo, Japan). This acquisition includes exclusive rights to Pitolisant in Japan and Spydia in Japan and other Asia-Pacific markets. This deal strengthens Viatrix' presence in the central nervous system and sleep disorder therapeutic areas across the region.
- [Merck](#) (NJ, USA) to acquire the chromatography business of [JSR Life Sciences](#) (Tokyo, Japan). This acquisition expands Merck's Protein A capabilities and strengthens its downstream bioprocessing portfolio.
- [Quintara Biosciences](#) (CA, USA) to acquire the Sanger sequencing business of [Laragen](#) (CA, USA). This deal strengthens service continuity and supports Quintara's strategic expansion in Los Angeles.
- [OSR Holdings](#) (Seoul, South Korea) to acquire [Woori IO](#) (Seoul, South Korea). This acquisition aims to advance noninvasive glucose monitoring technologies and transform diabetes care.

- [Novo Nordisk](#) (Bagsværd, Denmark) to acquire clinical-stage MASP-3 inhibitor Zaltenibart (OMS906) assets from [Omeros](#) (WA, USA). This asset purchase and license agreement expands Novo Nordisk's pipeline in complement-mediated disease therapies.
- [Precision BioLogic](#) (Dartmouth, Canada) to acquire [George King Bio-Medical](#) (KS, USA). This deal is intended to expand Precision BioLogic's presence in the global hemostasis diagnostics market and strengthen its portfolio of quality control plasma products.
- [XORTX Therapeutics](#) (Calgary, Canada) to acquire the renal anti-fibrotic therapeutic program from [Vectus Biosystems](#) (Sydney, Australia). This acquisition will enhance XORTX's pipeline in kidney disease treatments and support its strategic focus on innovative therapies for progressive renal disorders.

Partnerships

- [Kite Pharma](#) (CA, USA), a Gilead company, and [Pregene Biopharma Co., Ltd.](#) (Guangdong, China) announced a ~\$1.64B collaboration to co-develop next-generation in vivo CAR-T therapies targeting oncology, autoimmune, and other diseases.
- [Roche](#) (Switzerland) and [Hansoh Pharma](#) (China) announced a \$1.53B global licensing agreement granting Roche worldwide rights outside Greater China to HS-20110, a CDH17-targeting antibody-drug conjugate in Phase I development for colorectal and other solid tumors.
- [Rani Therapeutics](#) (CA, USA) and [Chugai Pharmaceutical Co., Ltd.](#) (Tokyo, Japan) announced a ~\$1.1B collaboration and license agreement to develop and commercialize an oral antibody therapy using Rani's RaniPill® platform for rare diseases.
- [Dianthus Therapeutics](#) (MA, USA) and [Leads Biolabs](#) (Nanjing, China) announced a ~\$1B exclusive license agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor for autoimmune diseases including lupus.
- [Nabla Bio](#) (MA, USA) and [Takeda Pharmaceuticals](#) (Tokyo, Japan) announced a ~\$1B AI-driven collaboration applying Nabla's JAM platform for de novo antibody and multispecific design across early programs.
- [Boehringer Ingelheim](#) (Germany) and [Aimed Bio Inc.](#) (Seoul, South Korea) announced a ~\$991M global collaboration and license agreement to develop a novel exatecan-based antibody-drug conjugate targeting a tumor-selective marker across multiple cancers, with first-in-human studies expected in 2026.

- [EVOQ Therapeutics](#) (IL, USA) and [Sanofi](#) (France) announced a ~\$500M collaboration to develop NanoDisc-based therapies aimed at restoring immune tolerance in autoimmune diseases.
- [AviadoBio](#) (London, United Kingdom) and [UgeneX Therapeutics](#) (Shanghai, China) entered a ~\$413M exclusive option and license deal for UGX-202, an AAV-based optogenetic gene therapy for retinitis pigmentosa.
- [SystImmune](#) (WA, USA) received a \$250M milestone payment from [Bristol Myers Squibb](#) (NJ, USA) after dosing the first patient in a Ph2/3 trial of iza-bren, a bispecific EGFR/HER3 ADC for TNBC.
- [Samsung C&T](#) and [Samsung Electronics](#) (South Korea) announced a \$110M investment and partnership with [GRAIL](#) (CA, USA) to launch the Galleri® multi-cancer early detection test in South Korea, with potential expansion to Japan and Singapore.
- [insitro](#) (CA, USA) and [Bristol Myers Squibb](#) (NJ, USA) extended their ALS collaboration for one year with up to \$20M, leveraging insitro's ChemML™ AI platform for novel therapies.
- [Turbine](#) (Budapest, Hungary) announced a collaboration with [AstraZeneca](#) (Cambridge, United Kingdom) to use its AI-powered Simulated Cell™ platform to accelerate ADC discovery and reduce experimental screening needs.
- [Alpenglow Biosciences](#) (WA, USA) and [Viridx](#) (MA, USA) announced a multi-year collaboration to develop AI-enabled prostate cancer diagnostics combining 3D pathology and MRI-based biophysics models.
- [iQure Pharma Inc.](#) (NJ, USA) and the [University of Padova](#) (Italy) partnered to study the mechanism of iQ-007, an EAAT2-targeted therapy restoring glutamate balance in CNS disorders.
- [Akadeum Life Sciences, Inc.](#) (MI, USA) and [BioIVT](#) (NY, USA) are collaborating to improve T cell quality for cell therapy using Akadeum's microbubble isolation and BioIVT's LEUKOMAX™ leukopakts.
- [CalciMedica](#) (CA, USA) and [Telperian Inc](#) (CA, USA) announced partnership to apply Telperian's AI-driven analytics to clinical data for Auxora™, supporting pivotal trial design in acute pancreatitis.
- [Synaptive Medical](#) (Toronto, Canada) and [Centile Bioscience](#) (London, United Kingdom) announced a partnership to integrate Centile's AI brain analytics into Modus Plan™, enhancing precision in neurosurgical planning.
- [Symrise AG](#) (Germany) and [Aplantex](#) (Montreal, Canada) partnered to co-develop plant-based bioactives via Aplantex's green biotech platform, following validation of key antioxidant compounds.
- [Stereotaxis](#) (MO, USA) and [CardioFocus](#) (MA, USA) partnered to advance the first robotic pulsed field ablation (PFA) system for cardiac arrhythmias, combining Centauri PFA with the MAGiC catheter.

- [Landmark Bio](#) (MA, USA) and [Mass General Brigham](#) (MA, USA) announced a collaboration to advance early-stage cell and gene therapies, with Landmark Bio providing development and manufacturing support through the Mass General Brigham Gene and Cell Therapy Institute.
- [Jacobio Pharma](#) (Beijing, China) announced a strategic partnership with [Oceanpine Capital](#) (Beijing, China) to advance its oncology pipeline and accelerate R&D growth.
- [Techsomed](#) (Rehovot, Israel) and [Medtronic](#) (MN, USA) announced a collaboration integrating Techsomed's AI-powered BioTracelO360™ software with Medtronic's Emprint™ microwave ablation system to enhance image-guided ablation therapy through real-time visualization, predictive margin control, and dynamic treatment planning.
- [Citius Oncology, Inc.](#) (NJ, USA) and [EVERSANA](#) (IL, USA) announced an exclusive agreement to support the U.S. launch of LYMPHIR™ for relapsed or refractory cutaneous T-cell lymphoma in Q4 2025.
- [Tempus AI](#) (IL, USA) and [Whitehawk Therapeutics](#) (NJ, USA) announced a multi-year collaboration to use Tempus' AI-driven real-world data to optimize biomarker research and clinical development for Whitehawk's antibody-drug conjugate (ADC) cancer programs.
- RetinalGenix Technologies, Inc. (FL, USA) and [Seer](#) (CA, USA) announced a collaboration to integrate ultra-high-resolution retinal imaging with advanced proteomic profiling to identify biomarkers for early detection and monitoring of neurodegenerative, retinal, and systemic diseases.
- [Taiho Pharmaceutical](#) (Japan) exercised its option under a 2017 agreement with [Arcus Biosciences](#) (CA, USA) to develop and commercialize casdatifan (AB521), a HIF-2α inhibitor for clear cell renal cell carcinoma, in Japan and parts of Asia.

Registered Direct Offering

- [Adicet Bio, Inc](#) (CA, USA) announced an \$80M underwritten registered direct offering of common stock and pre-funded warrants to support advancement of its allogeneic gamma delta T cell therapy programs for autoimmune diseases and cancer.
- [Humacyte](#) (NC, USA) announced a \$60M registered direct offering of common stock and warrants, with proceeds supporting the company's commercial-stage platform developing universally implantable, bioengineered human tissues.
- [Annovis Bio, Inc.](#) (PA, USA) announced a \$6M registered direct offering of common stock and pre-funded warrants to support working capital and general corporate purposes.

- [Envoy Medical](#) (MN, USA) announced a \$4M registered direct offering of common stock to support working capital and general corporate purposes.
- [Akari Therapeutics, Plc](#) (London, United Kingdom) announced a \$2.5M registered direct offering of ADSs and concurrent private placement of Series E and F warrants to support working capital and R&D of its novel ADC payload program.
- [bioAffinity Technologies](#) (TX, USA) announced a \$1.8M registered direct offering to support growing sales of its CyPath® Lung noninvasive lung cancer test and for general corporate purposes. WallachBeth Capital acted as sole placement agent.

Closures and Layoffs

- [Kezar Life Sciences](#) (CA, USA) to lay off 41 employees after the FDA canceled a key meeting to discuss the next trial for its lupus nephritis treatment, prompting the company to scale back operations and preserve resources.